top of page
HiveBio inaugural cohort 2025
Vasowatch was selected as one of ten companies to participate in this inaugural hybrid accelerator designed to provide support to underrepresented life science entrepreneurs.
MEDCity Invest Pitch Perfect presenter: HealthTech Payer/Provider Track
Vasowatch was featured as one of 24 innovators representing the best of current innovation in healthcare May 21, 2025.
Startup302 Life Science Pitch Competition - 2nd Place
Vasowatch was a finalist in the Delaware Prosperity Partnership's Startup302 Life Science Pitch Competition, focused on highlightiing high-growth, early-stage startups led by underrepresented founders. Vasowatch was one of nine companies selected from 100 entrants that have the potential to support Delaware's statewide economic development efforts to attract, grow and retain businesses, build a stronger entrepreneurial and innovation ecosystem, and support private employers in identifying, recruiting, and developing talent.
Seed2Table Featured Presenter
Vasowatch was one of five life science companies selected by Seed2Table, an organization that hosts exclusive events that connect startups with investors, influencers, government, and communities, to present at their May 7, 2025 Washington DC forum.
Southeast Venture Showcase
Vasowatch was selected as one of 48 groundbreaking disruptive startups to present at the Southeast Venture Showcase April 23, 2025, a gathering of the southeast region's leading research universities and federal laboratories to explore new possibilities that technology presents for the future.
Venturium 2025 Academic Venture Showcase Featured Life Science Presenter
Vasowatch was one of six featured Life Science companies presenting our investment opportunity to investors, strategic partners and industry leaders.
UCSF Rosenman Institute Innovators Semi-Finalist
Rosenman Innovators, a Med Tech accelerator program designed to catapult early-stage startups to the forefront of the industry, selected Vasowatch as a semi-finalist in their 2025 cohort.
Frontiers 2025 Startup Pitch Showcase
Featured startup at national event envisioning the future of Biotech at the Frontiers of Healthcare, AI, and Space. This gathering of investors, founders, and industry experts offered the opportunity to discuss trends, success stories, and transformative ideas driving the next wave of innovation.
What would it look like to predict Postpartum Hemorrhage? A Conversation with Christine Rohan & Dr. James Weimer
Vasowatch was honored to have our CEO, Christine Rohan, and Co-Founder, James Weimer, appear on a recent episode of the Making Sense of Pregnancy podcast. Check it out now!
Comcast NBCUniversal LIFT Labs "Top Pitch" Recipient
Vasowatch Inc was awarded the top prize at the January 30, 2025 "Top Pitch" event hosted at Comcast NBCUniversal LIFT Labs. Thanks to judges Kathleen Brunner, Mahesh Chand and Marc Lederman and sponsors the Philadelphia Alliance for Capital and Technologies (PACT), TiE Philadelphia and Ben Franklin Technology Partners of Southeastern Pennsylvania.
Mid-Atlantic Diamond Ventures Winter Forum Presenter
Mid-Atlantic Diamond Ventures (MADV) is an independent organization that assists emerging technology=based companies in their effort to build sustainable businesses by better positioning them for funding while increasing value at an early and crucial stage.
Penn Center of Innovation Ventures CEO of the Year
Christine Rohan, Vasowatch CEO, was selected by Penn Center of Innovation Ventures as CEO of the year across all of their portfolio companies.
Mid-Atlantic Capital Conference 2024
Featured startup presenter at the oldest, most established venture conference in the Mid-Atlantic.
Vasowatch named on of FEMHEALTH Insights' 5 Companies to Watch in Maternal Health
Vasowatch was selected as a key player driving maternal health advancements in the FemHealth Insights Maternal Health Report September 2024.
"Collectively, these companies are not only leading the FemTech maternal health vertical but are also setting new standards for the industry. Their innovations are paving the way for more personalized, effective, and safer maternal care solutions, highlighting the transformative potential of technology in addressing the complex challenges of maternal health. As they continue to devlop and refine their products, these companies are poised to play a pivotal role in shaping the future of maternal health care globally." - Brittany Baretto PhD, Ariella Tal
"Collectively, these companies are not only leading the FemTech maternal health vertical but are also setting new standards for the industry. Their innovations are paving the way for more personalized, effective, and safer maternal care solutions, highlighting the transformative potential of technology in addressing the complex challenges of maternal health. As they continue to devlop and refine their products, these companies are poised to play a pivotal role in shaping the future of maternal health care globally." - Brittany Baretto PhD, Ariella Tal
HITLAB Women's Health Tech Challenge Semi-Finalist
Selected as FemTech Innovator in the seventh annual HITLAB Women's Health Tech Initiative Challenge with a disruptive healthcare solution. The WHTC began in 2018, focusing on emerging technology applications and systems that improve medical care and the provision of healthcare among women worldwide, an industry slated to reach $50B by 2025.
Finalist | 2024 Harvard Business School Alumni New Venture Competition
Our team was selected as the Central Region finalist and winner for Harvard Business School Alumni New Venture Competition March 2024.
Invited to Present at Stanford Mussallem Center for Biodesign
Our team was invited to pitch at the Pediatric and Maternal Health Innovation Showcase at Stanford Mussallem Center for Biodesign on April 23, 2024.
Selected to Participate in IGNITE Healthcare Accelerator 2024
Selected to participate in a powerful community of supporting women founders with the capital, resources, and know-how required to support startup growth.
Vasowatch Selected as Member of ARPA-H Investor Catalyst Hub Spoke Network
We're excited to announce today that Vasowatch has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.
Vasowatch joins a dynamic nationwide network of organizations aligned to ARPA-H’s overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.
“Our spoke network embodies a rich and representative range of perspectives and expertise,” said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. “Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation.”
As an Investor Catalyst Hub spoke, Vasowatch gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.
The spoke network will continue to grow as the Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis. Interested organizations can visit https://investorcatalysthub.org/ to learn more or submit a membership application.
Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.
Vasowatch joins a dynamic nationwide network of organizations aligned to ARPA-H’s overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.
“Our spoke network embodies a rich and representative range of perspectives and expertise,” said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. “Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation.”
As an Investor Catalyst Hub spoke, Vasowatch gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.
The spoke network will continue to grow as the Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis. Interested organizations can visit https://investorcatalysthub.org/ to learn more or submit a membership application.
Startup of the Month!
We're honored to be recognized by the Penn Center for Innovation as their startup of the month for June 2024.
Vasowatch is a PCI Ventures portfolio company co-founded by Stefanie Modri, MSN, RN, C-MNN, Clinical Adjunct Professor at Penn Nursing, and James Weimer, PhD, a former Adjunct Assistant Professor in Computer and Information Science at Penn Engineering, focused on improving postpartum hemorrhage risk prediction in mothers.
Vasowatch is a PCI Ventures portfolio company co-founded by Stefanie Modri, MSN, RN, C-MNN, Clinical Adjunct Professor at Penn Nursing, and James Weimer, PhD, a former Adjunct Assistant Professor in Computer and Information Science at Penn Engineering, focused on improving postpartum hemorrhage risk prediction in mothers.
NSF Regional I-Corp Program
In April 2024, Vasowatch completed the NSF Regional I-Corps Program, executing customer discovery interviews with twenty-one clinicians, healthcare administrators and technologists, key opinion leaders and payers, and further honing Vasowatch’s value proposition and go-to-market strategy.
MATTER Health 51 Labs Maternal Mortality Accelerator Participants
CEO Christine Rohan presented the Vasowatch solution at the conclusion of the 51 Labs cohort. 51 Labs is a women's health accelerator focused on one simple question: how can we prevent maternal mortality in the U.S. before, during and after birth?
Vasowatch Presents 2024 Society for Maternal-Fetal Medicine's Pregnancy Meeting
Last week, the research upon which Vasowatch is based was presented during a podium speech at the 2024 Society for Maternal-Fetal Medicine's Pregnancy meeting (SMFM). There were over 2,000 entries and ours was one of the few accepted. This was an incredible accomplishment for our team of researchers and the future of Vasowatch for postpartum hemorrhage risk prediction.
In The News: Helping Black families to grow and thrive
To reverse the nationwide trend of serious harm and death before, during, and after childbirth for Black and other parents from marginalized groups, Penn Medicine is taking bold action to improve maternal health and eliminate racial disparities.
Click to read the full article.
Click to read the full article.
Vasowatch's 2023 Year in Review
As we turn the calendar over to 2024, we're excited about all that we accomplished last year and the momentum we have moving forward!
We're moving closer to commercializing our novel technology to improve maternal outcomes and health equity
Thank you for your support!
We're moving closer to commercializing our novel technology to improve maternal outcomes and health equity
Thank you for your support!
bottom of page